低分子肝素及其临床试验数据——各自的问题
Fractionating Heparins and Their Clinical Trial Data --Something for Everyone
摘要
肝素是由不同多糖单位和分子量组成的氨基葡聚糖，已证实可以在阿斯匹林基础之上进一步降低急性冠状动脉综合征（acute coronary syndrome，ACS）缺血事件的发生。 这使普通肝素成为2000年美国心脏病学会和美国心脏病协会（American College of Cardiology／American Heart Association，ACC／AHA）非ST段抬高ACS治疗指南的Ⅰ类指征^2。然而普通肝素也有其局限性，如治疗窗窄、动力学预测性差、血小板激活和不能抑制与血块结合的凝血酶。
出处
《美国医学会杂志（中文版）》
2005年第6期371-373,共3页
The Journal of the American Medical Association(Chinese Edition)
参考文献16
-
1Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. ,lAMA. 1996;276:811-815.
-
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the man-agement of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coil CardioL 2000:36:970-1062.
-
3Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999:100:1602-1608.
-
4Braunwald E, Antman EM, Beasley JW, et al. ACCIAHA guideline update forthe management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. Circulation. 2002;106:1893-1900.
-
5SYNERGY Executive Committee. The SYNERGY Trial: study design and rationale. Am Heart J. 2002;143:952-960.
-
6Blazing MA, de Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. TheA-to-Z Trial: methods and rationale for a single trial investigating combined useof low-molecular weight heparin with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001 ;142:211-217.
-
7Blazing MA, de Lemos JA, White HD, et al, for the A to Z Investigators. Safetyand efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA. 2004;292-55-64.
-
8The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes managedwith an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
-
9Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: asystematic review. JAMA. 2004;292:89-96.
-
10Montalescot G, Collet JP, Payot L, et al. Anti-Xa activity relates to outcome inacute coronary syndromes treated with enoxaparin. Circulation. 2004:108:1V-501.
-
1求求.治疗高血压需综合考虑心血管病风险因素[J].中华医学信息导报,2016,0(18):8-8.
-
2刘超.Graves眼病的诊断和治疗[J].临床内科杂志,2004,21(6):363-367. 被引量：6
-
3罗辉,于娜（图）.著名心血管专家胡大一认为:冠心病强化降脂时代已经到来[J].中国医药指南,2006,4(2):68-69.
-
4Selvin E.,Marinopoulos S.,Berkenblit G.,S.H. Golden,任付先.糖尿病患者糖化血红蛋白和心血管疾病的荟萃分析[J].世界核心医学期刊文摘（心脏病学分册）,2005,0(2):2-2.
-
5胰岛素有了“超长效”[J].中国家庭医生,2010(17):49-49.
-
6张伟,张心月,王新东.鱼腥草注射液治疗呼吸系统感染的Meta分析[J].中国药学杂志,2005,40(21):1674-1677. 被引量：6
-
7周红娟.川崎病并发冠状动脉病变的危险因素研究[J].当代医学,2014,20(34):59-60. 被引量：4
-
8Baglin T,Barrowcliffe TW,Coben A,Greaves M,陈君敏,曾开淇.肝素使用和监控指南[J].血栓与止血学,2006,12(1):42-48. 被引量：13
-
9高寒梅,郭龙枝,宋朝功.氯吡格雷冶疗非ST段抬高急性冠脉综合证临床观察[J].中国临床实用医学,2009,3(9):46-48. 被引量：1
-
10芦涤,郭乐凌,周琪.非ST段抬高急性冠状动脉综合征患者早期介入治疗前应用替罗非班近期预后的临床观察[J].中国综合临床,2007,23(10):865-867. 被引量：2
